RS58744B1 - Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje - Google Patents

Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje

Info

Publication number
RS58744B1
RS58744B1 RS20190433A RSP20190433A RS58744B1 RS 58744 B1 RS58744 B1 RS 58744B1 RS 20190433 A RS20190433 A RS 20190433A RS P20190433 A RSP20190433 A RS P20190433A RS 58744 B1 RS58744 B1 RS 58744B1
Authority
RS
Serbia
Prior art keywords
administration
liquid composition
patients requiring
requiring reduced
reduced volumes
Prior art date
Application number
RS20190433A
Other languages
English (en)
Serbian (sr)
Inventor
Srikanth Sundaram
Scott L Tarriff
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58744(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of RS58744B1 publication Critical patent/RS58744B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
RS20190433A 2012-03-20 2013-03-15 Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje RS58744B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261613173P 2012-03-20 2012-03-20
US201261669889P 2012-07-10 2012-07-10
US201261678715P 2012-08-02 2012-08-02
EP13765020.6A EP2827863B1 (en) 2012-03-20 2013-03-15 Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
PCT/US2013/032295 WO2013142359A1 (en) 2012-03-20 2013-03-15 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Publications (1)

Publication Number Publication Date
RS58744B1 true RS58744B1 (sr) 2019-06-28

Family

ID=49212373

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20230252A RS64137B1 (sr) 2012-03-20 2013-03-15 Tečne kompozicije bendamustina za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za primenu
RS20190433A RS58744B1 (sr) 2012-03-20 2013-03-15 Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20230252A RS64137B1 (sr) 2012-03-20 2013-03-15 Tečne kompozicije bendamustina za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za primenu

Country Status (17)

Country Link
US (3) US9000021B2 (ja)
EP (3) EP2827863B1 (ja)
JP (6) JP6224064B2 (ja)
CN (2) CN107157988A (ja)
CA (1) CA2867343C (ja)
DK (2) DK2827863T3 (ja)
ES (2) ES2943668T3 (ja)
FI (1) FI3533447T3 (ja)
HK (1) HK1243346A1 (ja)
HR (2) HRP20230276T1 (ja)
HU (2) HUE062230T2 (ja)
LT (1) LT2827863T (ja)
PL (2) PL3533447T3 (ja)
PT (2) PT2827863T (ja)
RS (2) RS64137B1 (ja)
SI (2) SI2827863T1 (ja)
WO (1) WO2013142359A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55491B2 (sr) 2010-01-28 2020-11-30 Eagle Pharmaceuticals Inc Formulacije bendamustina
EP2827863B1 (en) 2012-03-20 2019-01-16 Eagle Pharmaceuticals, Inc. Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
RS65177B1 (sr) * 2012-03-20 2024-03-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
JPWO2021014957A1 (ja) * 2019-07-22 2021-01-28
WO2021161876A1 (ja) * 2020-02-10 2021-08-19 富士フイルム株式会社 ベンダムスチン液剤
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (ja) 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
CN1138827A (zh) 1994-01-24 1996-12-25 普罗克特和甘保尔公司 使难溶药物活性物增溶的方法
KR100627614B1 (ko) 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
TW200621240A (en) 2004-11-05 2006-07-01 Salmedix Inc Cancer treatments
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JPWO2007026771A1 (ja) * 2005-08-31 2009-03-12 小野薬品工業株式会社 点滴用注射剤
AU2007285215A1 (en) 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
UA109109C2 (uk) 2009-01-15 2015-07-27 Сефалон, Інк. Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
ES2525257T3 (es) 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CA2760085A1 (en) 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
CN101584668A (zh) * 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
RS55491B2 (sr) * 2010-01-28 2020-11-30 Eagle Pharmaceuticals Inc Formulacije bendamustina
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
WO2012015810A2 (en) 2010-07-28 2012-02-02 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
TWI640537B (zh) 2011-12-05 2018-11-11 Ｘ 染色體有限公司 ＰＤＧＦ受體β結合多肽
EP2806872A4 (en) * 2012-01-24 2014-12-03 Innopharma Inc BENDAMUSTIN COMPOSITIONS AND RELATED METHODS
JP2015506989A (ja) 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
RS65177B1 (sr) 2012-03-20 2024-03-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
EP2827863B1 (en) 2012-03-20 2019-01-16 Eagle Pharmaceuticals, Inc. Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Also Published As

Publication number Publication date
PT3533447T (pt) 2023-05-17
LT2827863T (lt) 2019-06-10
HUE062230T2 (hu) 2023-10-28
US20130253026A1 (en) 2013-09-26
PL2827863T3 (pl) 2019-07-31
DK3533447T3 (da) 2023-04-24
JP2018048153A (ja) 2018-03-29
US9579384B2 (en) 2017-02-28
PL3533447T3 (pl) 2023-07-17
ES2718902T3 (es) 2019-07-05
CN104271135B (zh) 2017-05-17
WO2013142359A1 (en) 2013-09-26
US9000021B2 (en) 2015-04-07
SI2827863T1 (sl) 2019-06-28
US20150343061A1 (en) 2015-12-03
JP2018197248A (ja) 2018-12-13
EP2827863B1 (en) 2019-01-16
JP2020143143A (ja) 2020-09-10
US20150080444A1 (en) 2015-03-19
DK2827863T3 (en) 2019-04-23
CN107157988A (zh) 2017-09-15
HUE044233T2 (hu) 2019-10-28
HRP20230276T1 (hr) 2023-04-28
JP6381761B2 (ja) 2018-08-29
CA2867343A1 (en) 2013-09-26
JP6738376B2 (ja) 2020-08-12
HRP20190693T1 (hr) 2019-10-04
EP2827863A4 (en) 2015-11-18
JP2015510940A (ja) 2015-04-13
PT2827863T (pt) 2019-05-13
RS64137B1 (sr) 2023-05-31
SI3533447T1 (sl) 2023-06-30
EP4218756A1 (en) 2023-08-02
FI3533447T3 (fi) 2023-05-04
JP2024037915A (ja) 2024-03-19
ES2943668T3 (es) 2023-06-15
JP2022028813A (ja) 2022-02-16
EP3533447B1 (en) 2023-03-15
HK1243346A1 (zh) 2018-07-13
EP3533447A1 (en) 2019-09-04
CN104271135A (zh) 2015-01-07
EP2827863A1 (en) 2015-01-28
CA2867343C (en) 2020-08-11
JP6224064B2 (ja) 2017-11-01

Similar Documents

Publication Publication Date Title
PL2827863T3 (pl) Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
HRP20181378T1 (hr) Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom
HK1194696A1 (zh) 用於受控輸送醫用流體的系統
IL229474A0 (en) Cannabinoids for use in the treatment of neuropathic pain
EP2788075A4 (en) DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
PL2773648T3 (pl) Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile
PL2644215T3 (pl) Aparat do pozaustrojowej obróbki krwi
HK1210271A1 (en) Ophthalmic devices for delivery of beneficial agents
HK1172569A1 (en) Chinese medicine composition for treating colds and preparation method thereof
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
EP2865380A4 (en) USE OF INULA LINEARIIFOLIA LACTONE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MYOCARDITIS
EP2832434A4 (en) METHOD FOR TREATING SIMULTANEOUS CAVITATION OF LIQUID MEDIA OF DIFFERENT COMPOSITIONS
GB201218084D0 (en) Novel compounds and methods for use in medicine
EP2934632A4 (en) DEVICE AND METHOD FOR INHIBITING THE MOVEMENT OF A MEDICAL DEVICE IN A PATIENT
GB2508897B (en) Oxygen flow controller for medical use
IL231531A (en) Use of strigolactones and their analogues for the preparation of drugs for the treatment of cancerous growth conditions
GB201209198D0 (en) Liquid treatment
GB201209283D0 (en) Liquid treatment
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds